Executives Depart Cassava, Maker of Disputed Alzheimer’s Drug

Written by

in

The New York Times – Business:

The chief executive and a lead scientist stepped down weeks after a federal grand jury filed fraud charges against a research collaborator.

This post first appeared in The New York Times – Business. Read the original article.